PRESS RELEASE published on 06/15/2023 at 07:45, 2 years 5 months ago Marinomed Biotech AG prepares launch of Carragelose eye drops in 2024
PRESS RELEASE published on 05/23/2023 at 07:45, 2 years 6 months ago Marinomed Biotech AG reports best first quarter in company history
PRESS RELEASE published on 04/19/2023 at 07:45, 2 years 7 months ago Marinomed Biotech AG with Carragelose record sales in 2022 and positive outlook for 2023
PRESS RELEASE published on 04/12/2023 at 07:45, 2 years 7 months ago Marinomed Biotech AG publishes clinical data on the effectiveness of its Carragelose nasal spray in the treatment of hay fever
PRESS RELEASE published on 03/14/2023 at 07:45, 2 years 8 months ago Marinomed Biotech AG reports positive clinical data for the Carragelose decongestant nasal spray
PRESS RELEASE published on 02/16/2023 at 07:45, 2 years 9 months ago Marinomed Biotech AG announces preliminary revenue for 2022 with double-digit growth for Carragelose
Published on 12/05/2025 at 02:35, 4 hours 42 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 6 hours 17 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 8 hours 12 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 8 hours 17 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 07:00, 17 minutes ago Swiss Re targets a net income of USD 4.5 billion in 2026; refreshed strategy to strengthen core business
Published on 12/05/2025 at 03:30, 3 hours 46 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 7 hours 26 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 10 hours 51 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 11 hours 2 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 18:00, 13 hours 17 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 13 hours 32 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 13 hours 33 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 13 hours ago Declaration of voting rights at the end of November 2025
